Efficacy of continuous subcutaneous insulin infusion in Type 1 diabetes: A 2-year perspective using the established criteria for funding from a National Health Service

Diabetic Medicine

Volumn 24, Issue 12, 2007, Pages 1419-1423

  Gimenez M ^b   Conget, I ^a,b   Jansa M ^b   Vidal, M ^b   Chiganer, G ^b   Levy, I ^b  

^a Endocrinology and Diabetes Unit   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Continuous subcutaneous insulin infusion; National Health Service; Type 1 diabetes

Indexed keywords

HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN LISPRO; NEUTRAL INSULIN;

ADULT; BODY MASS; CONTINUOUS INFUSION; DIABETIC KETOACIDOSIS; DISEASE DURATION; DRUG EFFICACY; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH SERVICE; QUALITY OF LIFE; REVIEW;

ADULT; BODY MASS INDEX; DIABETES MELLITUS, TYPE 1; DIABETIC KETOACIDOSIS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INFUSION PUMPS, IMPLANTABLE; INSULIN; INSULIN INFUSION SYSTEMS; MALE; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 36549007416     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2007.02287.x     Document Type: Review

References (21)

1. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993 329 : 977 986.
2. American Diabetes Association. Implications of the Diabetes Control and Complications Trial. Diabetes Care 2003 26 : S25 S27.
3. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005 353 : 2643 2653.
4. Cefalu WT. Glycemic control and cardiovascular disease - should we reassess clinical goals? N Engl J Med 2005 353 : 2707 2709.
5. Adverse events and their association with treatment regimens in the Diabetes Control and Complications Trial. Diabetes Care 1995 18 : 1415 1427.
6. Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 2002 25 : 593 598.
7. Pickup JC. Are insulin pumps underutilized in type 1 diabetes? Yes. Diabetes Care 2006 29 : 1449 1452.
8. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. Br Med J 2002 324 : 705.
9. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care 2003 26 : 1079 1087.
10. Roze S, Valentine WJ, Zakrzewska KE, Palmer AJ. Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK. Diabet Med 2005 22 : 1239 1245.
11. Colquitt JL, Green C, Sidhu MK, Hartwell D, Waugh N. Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes. Health Technol Assess 2004 8 : 1 171.
12. Scuffham P, Carr L. The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes. Diabet Med 2003 20 : 586 593.
13. Hoogma RP, Spijker AJ, Doorn-Scheele M, van Doorn TT, Michels RP, van Doorn RG et al. Quality of life and metabolic control in patients with diabetes mellitus type 1 treated by continuous subcutaneous insulin infusion or multiple daily insulin injections. Neth J Med 2004 62 : 383 387.
14. Hoogma RP, Hammond PJ, Gomis R, Kerr O, Bruttomeso D, Bouter KP et al. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial. Diabet Med 2006 23 : 141 147.
15. The DCCT Research Group. Reliability and validity of a diabetes quality-of-life measure for the Diabetes Control and Complications Trial. Diabetes Care 1988 11 : 725 732.
16. Jenkinson C, Layte R. Development and testing of the UK SF-12 (short form health survey). J Health Serv Res Policy 1997 2 : 14 18.
17. Chantelau E, Spraul M, Muhlhauser I, Gause R, Berger M. Long-term safety, efficacy and side-effects of continuous subcutaneous insulin infusion treatment for type 1 (insulin-dependent) diabetes mellitus: a one-centre experience. Diabetologia 1989 32 : 421 426.
18. Rodrigues IA, Reid HA, Ismail K, Amiel SA. Indications and efficacy of continuous subcutaneous insulin infusion (CSII) therapy in Type 1 diabetes mellitus: a clinical audit in a specialist service. Diabet Med 2005 22 : 842 849.
19. Linkeschova R, Raoul M, Bott U, Berger M, Spraul M. Less severe hypoglycaemia, better metabolic control, and improved quality of life in Type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. Diabet Med 2002 19 : 746 751.
20. Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type I diabetes. Diabetes Care 1996 19 : 324 327.
21. Conget I, Jansa M, Vidal M, Vidal J, Manzanares JM, Gomis R. Effects of an individual intensive educational control program for insulin-dependent diabetic subjects with poor metabolic control. Diabetes Res Clin Pract 1995 27 : 189 192.